Roche, immatics sign cancer R&D deal potentially worth more than $1B

11/14/2013 | Genetic Engineering & Biotechnology News

Roche Holding and German firm immatics biotechnologies agreed to collaborate in the development and commercialization of tumor-associated peptide-based cancer vaccines and other cancer immunotherapies, primarily for stomach, lung and prostate cancers. The partners will use immatics' technology to find candidates for cancer vaccine development and other cancer targets. The deal entitles immatics to $17 million upfront, research funding and potentially more than $1 billion in milestone fees and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA